Bio-Rad Laboratories Inc. (BIO)

339.73
1.39 0.41
NYSE : Health Technology
Prev Close 338.34
Open 338.98
Day Low/High 337.68 / 343.98
52 Wk Low/High 220.05 / 345.50
Volume 133.32K
Avg Volume 185.10K
Exchange NYSE
Shares Outstanding 24.70M
Market Cap 10.04B
EPS 12.20
P/E Ratio 11.22
Div & Yield N.A. (N.A)

Latest News

Bio-Rad Reports Second-Quarter 2019 Financial Results

Bio-Rad Reports Second-Quarter 2019 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2019.

Delaware District Court Grants Bio-Rad's Motion For Permanent Injunction Against 10X Genomics

Delaware District Court Grants Bio-Rad's Motion For Permanent Injunction Against 10X Genomics

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announces that today the Delaware District Court granted Bio-Rad's motion for permanent injunction against 10X Genomics from making...

Bio-Rad To Report Second-Quarter 2019 Financial Results

Bio-Rad To Report Second-Quarter 2019 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market.

Moody's Upgrades Bio-Rad To Baa2, Reflecting Recent Improvement In The Company's Operating Performance

Moody's Upgrades Bio-Rad To Baa2, Reflecting Recent Improvement In The Company's Operating Performance

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody's Investors Service ("Moody's") upgraded the unsecured rating of Bio-Rad Laboratories, Inc.

Bio-Rad To Participate In Goldman Sachs Annual Global Healthcare Conference On June 11

Bio-Rad To Participate In Goldman Sachs Annual Global Healthcare Conference On June 11

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the...

Bio-Rad To Participate At Jefferies 2019 Global Healthcare Conference On June 4

Bio-Rad To Participate At Jefferies 2019 Global Healthcare Conference On June 4

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in...

Bio-Rad Reports First Quarter 2019 Financial Results

Bio-Rad Reports First Quarter 2019 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.

Bio-Rad To Participate In The Bank Of America Merrill Lynch Health Care Conference 2019 In May

Bio-Rad To Participate In The Bank Of America Merrill Lynch Health Care Conference 2019 In May

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the...

Bio-Rad Appoints Andrew Last As Executive Vice President And Chief Operating Officer

Bio-Rad Appoints Andrew Last As Executive Vice President And Chief Operating Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr.

Bio-Rad To Report First-Quarter 2019 Financial Results

Bio-Rad To Report First-Quarter 2019 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market.

Bio-Rad Receives U.S. FDA Clearance For The IH-500, Expanding Its Offering For The Blood Testing Market

Bio-Rad Receives U.S. FDA Clearance For The IH-500, Expanding Its Offering For The Blood Testing Market

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.

Bio-Rad Names Ilan Daskal Executive Vice President And Chief Financial Officer

Bio-Rad Names Ilan Daskal Executive Vice President And Chief Financial Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019.

Bio-Rad Announces Innovative Test To Aid In The Diagnosis Of Lyme Disease With The FDA Clearance Of The BioPlex 2200 Lyme Total Assay

Bio-Rad Announces Innovative Test To Aid In The Diagnosis Of Lyme Disease With The FDA Clearance Of The BioPlex 2200 Lyme Total Assay

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.

Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing

Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the "NYSE") stating that the Company is...

Bio-Rad Reports Fourth-Quarter And Full-Year 2018 Financial Results

Bio-Rad Reports Fourth-Quarter And Full-Year 2018 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018.

Bio-Rad Releases First FDA-Cleared Digital PCR System And Test For Monitoring Chronic Myeloid Leukemia Treatment Response

Bio-Rad Releases First FDA-Cleared Digital PCR System And Test For Monitoring Chronic Myeloid Leukemia Treatment Response

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS...

Bio-Rad To Report Fourth-Quarter And Full-Year 2018 Financial Results Thursday, February 28, 2019

Bio-Rad To Report Fourth-Quarter And Full-Year 2018 Financial Results Thursday, February 28, 2019

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2018 on Thursday, February 28, 2019, following the close of...

Christine Tsingos Announces Plans To Retire As CFO Of Bio-Rad Laboratories, Inc. Effective April 30, 2019

Christine Tsingos Announces Plans To Retire As CFO Of Bio-Rad Laboratories, Inc. Effective April 30, 2019

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A.

Bio-Rad To Participate At The 37th Annual J.P. Morgan Healthcare Conference On January 8

Bio-Rad To Participate At The 37th Annual J.P. Morgan Healthcare Conference On January 8

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate...

Bio-Rad Quality Controls Now Available For Multiple Abbott Clinical Diagnostics Platforms

Bio-Rad Quality Controls Now Available For Multiple Abbott Clinical Diagnostics Platforms

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company's quality controls across multiple Abbott clinical diagnostics platforms that...

Bio-Rad And The University Of Chicago Win Patent Infringement Case Against 10X Genomics Related To Droplet Microfluidics Technologies

Bio-Rad And The University Of Chicago Win Patent Infringement Case Against 10X Genomics Related To Droplet Microfluidics Technologies

A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc.

Bio-Rad Wins USDA Contract For Its Pathogen Detection Testing Products

Bio-Rad Wins USDA Contract For Its Pathogen Detection Testing Products

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the...

Bio-Rad Reports Third-Quarter 2018 Financial Results

Bio-Rad Reports Third-Quarter 2018 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2018.

Notable Monday Option Activity: BIO, FSLR, APPF

Notable Monday Option Activity: BIO, FSLR, APPF

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bio-Rad Laboratories Inc , where a total volume of 4,006 contracts has been traded thus far today, a contract volume which is representative of approximately 400,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 260.8% of BIO's average daily trading volume over the past month, of 153,625 shares.

Bio-Rad Receives U.S. FDA Clearance For The IH-Reader 24, Expanding The Company's Offering For The Blood Typing Market

Bio-Rad Receives U.S. FDA Clearance For The IH-Reader 24, Expanding The Company's Offering For The Blood Typing Market

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.

Bio-Rad To Report Third-Quarter 2018 Financial Results Thursday, November 1, 2018

Bio-Rad To Report Third-Quarter 2018 Financial Results Thursday, November 1, 2018

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2018 on Thursday, November 1, 2018, following the close of the market.

Bio-Rad To Participate At The Morgan Stanley 16th Annual Global Healthcare Conference On September 12

Bio-Rad To Participate At The Morgan Stanley 16th Annual Global Healthcare Conference On September 12

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate...

Bio-Rad Reports Second-Quarter 2018 Financial Results

Bio-Rad Reports Second-Quarter 2018 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2018.

TheStreet Quant Rating: B+ (Buy)